Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec 1;42(45):4638-4651.
doi: 10.1093/eurheartj/ehab246.

Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis

Eliano P Navarese  1   2   3 , Alexandra J Lansky  4 , Dean J Kereiakes  5 , Jacek Kubica  1   3 , Paul A Gurbel  6 , Diana A Gorog  7   8 , Marco Valgimigli  9 , Nick Curzen  10   11 , David E Kandzari  12 , Marc P Bonaca  13 , Marc Brouwer  14 , Julia Umińska  15 , Milosz J Jaguszewski  16 , Paolo Raggi  2 , Ron Waksman  17 , Martin B Leon  18   19 , William Wijns  20 , Felicita Andreotti  21   22
Affiliations
Meta-Analysis

Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis

Eliano P Navarese et al. Eur Heart J. .

Abstract

Aims: The value of elective coronary revascularisation plus medical therapy over medical therapy alone in managing stable patients with coronary artery disease is debated. We reviewed all trials comparing the two strategies in this population.

Methods and results: From inception through November 2020, MEDLINE, EMBASE, Google Scholar, and other databases were searched for randomised trials comparing revascularisation against medical therapy alone in clinically stable coronary artery disease patients. Treatment effects were measured by rate ratios (RRs) with 95% confidence intervals, using random-effects models. Cardiac mortality was the pre-specified primary endpoint. Spontaneous myocardial infarction (MI) and its association with cardiac mortality were secondary endpoints. Further endpoints included all-cause mortality, any MI, and stroke. Longest follow-up data were abstracted. The study is registered with PROSPERO (CRD42021225598). Twenty-five trials involving 19 806 patients (10 023 randomised to revascularisation plus medical therapy and 9783 to medical therapy alone) were included. Compared with medical therapy alone, revascularisation yielded a lower risk of cardiac death [RR 0.79 (0.67-0.93), P < 0.01] and spontaneous MI [RR 0.74 (0.64-0.86), P < 0.01]. By meta-regression, the cardiac death risk reduction after revascularisation, compared with medical therapy alone, was linearly associated with follow-up duration [RR per 4-year follow-up: 0.81 (0.69-0.96), P = 0.008], spontaneous MI absolute difference (P = 0.01) and percentage of multivessel disease at baseline (P = 0.004). Trial sequential and sensitivity analyses confirmed the reliability of the cardiac mortality findings. All-cause mortality [0.94 (0.87-1.01), P = 0.11], any MI (P = 0.14), and stroke risk (P = 0.30) did not differ significantly between strategies.

Conclusion: In stable coronary artery disease patients, randomisation to elective coronary revascularisation plus medical therapy led to reduced cardiac mortality compared with medical therapy alone. The cardiac survival benefit after revascularisation improved with longer follow-up times and was associated with fewer spontaneous MIs.

Keywords: Coronary; Elective; Medical therapy; Meta-analysis; Randomised trials; Revascularisation.

PubMed Disclaimer

Figures

None
Major findings on cardiac mortality reduction with elective coronary revascularisation plus medical therapy vs. medical therapy alone. Abbreviations in text.
Figure 1
Figure 1
Study selection. ACS, acute coronary syndrome; HF, heart failure.
Figure 2
Figure 2
(A) Rate ratios and 95% confidence intervals for cardiac mortality with revascularisation plus medical therapy vs. medical therapy alone. Size of data markers is proportional to weight in meta-analysis. CI, confidence interval; MT, medical therapy; P-Y, person-years; RR, rate ratio. (B) Meta-analyses for cardiac death and spontaneous myocardial infarction excluding studies enrolling only post-acute coronary syndrome patients, chronic total occlusions, and use of coronary artery bypass grafting >30% in the revascularisation plus medical therapy arm. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CI, confidence interval; CTO, chronic total occlusion; MT, medical therapy; P-Y, person-years; RR, rate ratio. (C) Meta-regression of rate ratios for cardiac mortality with revascularisation plus medical therapy vs. medical therapy alone in relation to follow-up duration. Size of data markers is proportional to size of trial. The solid line represents the meta-regression slope of the change in cardiac death rate ratio for revascularisation plus medical therapy vs. medical therapy alone with increasing length of follow-up. Rate ratios lower than 1 indicate cardiac death reduction with revascularisation. RR, rate ratio; MT, medical therapy.
Figure 2
Figure 2
Continued.
Figure 3
Figure 3
(A) Rate ratios and 95% confidence intervals for spontaneous myocardial infarction with revascularisation plus medical therapy vs. medical therapy alone. Size of data markers is proportional to weight in meta-analysis. CI, confidence interval; MI, myocardial infarction; MT, medical therapy; P-Y, person-years; RR, rate ratio. (B) Meta-regression of rate ratios for cardiac mortality with revascularisation plus medical therapy vs. medical therapy alone in relation to absolute difference in spontaneous myocardial infarction. Size of data markers is proportional to size of trial. The solid line represents the meta-regression slope of the change in cardiac death rate ratio for revascularisation plus medical therapy vs. medical therapy alone across increasing absolute differences for myocardial infarction. Rate ratios lower than 1 indicate cardiac death reduction with revascularisation. MI, myocardial infarction; RR, rate ratio; MT, medical therapy.
See this image and copyright information in PMC

Comment in

References

    1. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1160–1203. - PMC - PubMed
    1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477. - PubMed
    1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO.. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165. - PubMed
    1. Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, Devito F, Zito A, Occhipinti M, Castiglioni B, Calveri G, Maisano F, Ciccone MM, De Servi S, Navarese EP.. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail 2017;10:e003255. - PubMed
    1. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382:1395–1407. - PMC - PubMed

MeSH terms